Compare LWAY & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWAY | DBVT |
|---|---|---|
| Founded | 1986 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.4M | 508.8M |
| IPO Year | 1987 | N/A |
| Metric | LWAY | DBVT |
|---|---|---|
| Price | $23.75 | $19.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $35.00 | $31.75 |
| AVG Volume (30 Days) | 61.7K | ★ 763.5K |
| Earning Date | 11-12-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $204,069,000.00 | $5,502,000.00 |
| Revenue This Year | $15.79 | $1,768.71 |
| Revenue Next Year | $13.17 | $1,028.88 |
| P/E Ratio | $32.15 | ★ N/A |
| Revenue Growth | ★ 12.14 | N/A |
| 52 Week Low | $19.50 | $2.93 |
| 52 Week High | $34.20 | $26.19 |
| Indicator | LWAY | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 56.61 |
| Support Level | $23.03 | $18.46 |
| Resistance Level | $25.66 | $22.89 |
| Average True Range (ATR) | 0.98 | 1.82 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 39.16 | 41.17 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through direct sales force, brokers, and distributors.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.